1	The Impact of COVID-19 on Cancer Screening and Treatment in Older Adults: The
2	Multiethnic Cohort Study
3	
4	Authors: Victoria P. Mak ¹ , Kami White ¹ , Lynne R. Wilkens ¹ , Iona Cheng ² , Christopher
5	Haiman ³ , Loïc Le Marchand ¹
6	
7	Authors Affiliation:
8	1. Population Sciences in the Pacific Program, University of Hawai'i Cancer Center
9	2. University of California San Francisco
10	3. Center for Genetic Epidemiology, University of Southern California
11	
12	Keywords: COVID-19, Health-related Behaviors, Cancer Screening, Lifestyle Factors,
13	Multiethnic Cohort
14	
15	ACKNOWLEDGEMENTS
16	This research was partially supported by the Omidyar 'Ohana Foundation and
17	grant U01 CA164973 from the National Cancer Institute. Special thanks to Faye
18	Nagamine, Yunoh Jung, and Anne Tome for assistance with data collection, data
19	management, and statistical analysis.
20	

21

ABSTRACT

22 Background:

23 The Coronavirus Disease of 2019 (COVID-19) has impacted the health and day-24 to-day life of individuals, especially the elderly and people with certain pre-existing 25 medical conditions, including cancer. The purpose of this study was to investigate how 26 COVID-19 impacted access to cancer screenings and treatment, by studying the 27 participants in the Multiethnic Cohort (MEC) study. 28 Methods: 29 The MEC has been following over 215,000 residents of Hawai'i and Los Angeles 30 for the development of cancer and other chronic diseases since 1993-1996. It includes 31 men and women of five racial and ethnic groups: African American, Japanese American, 32 Latino, Native Hawaiian, and White. In 2020, surviving participants were sent an 33 invitation to complete an online survey on the impact of COVID-19 on their daily life 34 activities, including adherence to cancer screening and treatment. Approximately 7,000 35 MEC participants responded. A cross-sectional analysis was performed to investigate 36 the relationships between the postponement of regular health care visits and cancer 37 screening procedures or treatment with race and ethnicity, age, education, and 38 comorbidity.

39 **Results:**

Women with more education, women with lung disease, COPD, or asthma, and
women and men diagnosed with cancer in the past 5 years were more likely to
postpone any cancer screening test/procedure due to the COVID-19 pandemic. Groups

43 less likely to postpone cancer screening included older women compared to younger

44 women and Japanese American men and women compared to White men and women.

45 **Conclusions:**

46 This study revealed specific associations of race/ethnicity, age, education level,

47 and comorbidities with the cancer-related screening and healthcare of MEC participants

48 during the COVID-19 pandemic. Increased monitoring of patients in high-risk groups for

49 cancer and other diseases is of the utmost importance as the chance of undiagnosed

50 cases or poor prognosis is increased as a result of delayed screening and treatment.

51 **Funding:**

52 This research was partially supported by the Omidyar 'Ohana Foundation and 53 grant U01 CA164973 from the National Cancer Institute.

55

INTRODUCTION

56 The highly contagious Coronavirus Disease of 2019 (COVID-19) has impacted 57 the health and day-to-day life of individuals, especially the elderly and people with 58 certain preexisting medical conditions, including cancer. COVID-19 was declared a 59 worldwide pandemic on March 11, 2020, after its discovery in late December 2019. As 60 of January 30, 2023, 6,831,427 deaths had been reported among 670,507,704 cases 61 worldwide.¹ Due to the rapid spread and high infectivity rates, stay-at-home orders were 62 decreed to allow for physical distancing and self-isolation. Populations at high risk of 63 contracting COVID-19 and developing severe illness were the elderly and people of all 64 ages with pre-existing medical conditions (such as diabetes, high blood pressure, heart 65 disease, lung disease, or cancer).²

66 Cancer patients were not only at a higher risk of severe illness from COVID-19 67 but changes in cancer care were also reported. One example is the finding of the 68 COVID-19 and Cancer Outcomes Study, which is a multicenter prospective cohort study 69 comprised of adult patients with a current or history of hematological malignancy or 70 invasive solid tumor, who were scheduled for an outpatient medical oncology visit at the 71 Tisch Cancer Institute in New York City or the Dana-Farber Cancer Institute in Boston. 72 Researchers found that 10% of patients in the cohort had treatment delayed during the 73 pandemic and, of that subset, 48% had treatment delayed due to a COVID-19 diagnosis.³ In the United States, COVID-19 disproportionately affected racial and ethnic 74 75 minorities, particularly African Americans, with an observed two-fold higher rate of 76 hospitalization and a greater than two-fold higher rate of death, as compared to Non-Hispanic Whites.⁴ The disparity seen with COVID-19 was consistent with patterns of 77

78 disparities observed for cancer; it is well-documented that 5-year survival rates for 79 multiple cancers are lower in African Americans compared to White Americans. While 80 cancer is a multifactorial disease that is influenced by genetic and environmental factors. 81 COVID-19 is an infectious disease that is enabled by the cellular expression of 82 angiotensin-converting enzyme 2 (ACE2) receptors. However, preexisting comorbidities, 83 socioeconomic disadvantages, living conditions, health literacy, and access to health care appear to fuel underlying risks for both cancer and COVID-19 disparities.⁴ 84 85 In addition, the pandemic has affected access to cancer screenings, especially 86 for colorectal cancer (CRC) and breast cancer. The recommendation for CRC screening 87 among average-risk adults aged 50 to 75 years is to undergo an annual fecal immunochemical test (FIT) or colonoscopy every 10 years.⁵ Screening and appropriate 88 89 follow-up can reduce incidence and mortality, which is important because CRC is the second leading cause of cancer death in the United States.⁶ One study found that CRC 90 91 screening rates are particularly low in Hispanic and Asian American adults, recent immigrants, those with low incomes, and the uninsured.⁶ During the COVID-19 92 pandemic, colorectal cancer screenings were reported to have dropped by 84.5% at a 93 network of 20 United States institutions with more than 28 million patients.⁷ 94 95 For breast cancer, which is the most common non-cutaneous malignancy and the 2nd most lethal tumor among women in the US, the recommendation is biennial 96 mammography in women ages 50 to 74 years.⁵ In the MEC, Native Hawaiian 97 98 participants have the highest risk of breast cancer, followed by Japanese American and White participants.⁸ Nationwide, the breast cancer mortality rate is 40% higher for 99 African American patients compared with White patients.⁹ During the COVID-19 100

pandemic, breast cancer screenings dropped by 89.2% at a network of 20 United States
 institutions with more than 28 million patients.⁷

103 Lastly, studies have suggested that educational attainment is associated with 104 adherence to cancer screening. For breast cancer, a positive association was found between education level and adherence to mammography screening.¹⁰ For colorectal 105 106 cancer, a study on United States veterans aged 50-75 years concluded that both 107 education and income show a statistically significant dose-dependent direct association with screening.¹¹ 108 109 In summary, COVID-19 has impacted medical care delivery, access to cancer 110 screening, and the day-to-day life of individuals worldwide. However, the full impact of 111 the pandemic on cancer screenings and cancer care is not entirely known. The purpose

112 of this cross-sectional study was to understand how COVID-19 affected access to

113 cancer screening and treatment, by studying the participants in the Multiethnic Cohort

114 (MEC) study.

115

METHODS

116 Study Population

117 The Multiethnic Cohort (MEC) was established in 1993 – 1996 at the University 118 of Hawai'i Cancer Center (UHCC) and the University of Southern California (USC) with 119 the goals of elucidating lifestyle and genetic risk factors responsible for explaining the ethnic/racial disparities that exist for cancer and other chronic diseases.¹² The cohort 120 121 has followed over 215,000 residents of Hawai'i and Los Angeles, aged 45 to 75 years old at recruitment, and includes men and women of five main ethnic and racial origins: 122 123 African American, Japanese American, Latino, Native Hawaiian, and White. Participants 124 entered the cohort by returning a 26-page mailed guestionnaire. They also were sent 125 follow-up questionnaires every five years. Disease ascertainment was primarily 126 conducted by linking the cohort to SEER cancer registries, death certificate registries, 127 CA hospital discharge diagnoses, and Medicare. Approximately 100,000 MEC members 128 (median age: 82) were still alive as of 2019. Demographics (i.e., race/ethnicity, 129 maximum years of education attained, birthplace), pre-existing and incident disease 130 outcomes, and lifestyle risk factors were available from the MEC database. 131 **Study Design**

In May 2020, MEC participants were invited to participate in an online survey (implemented in Qualtrics) on the impact of COVID-19 on their everyday life and healthrelated behaviors. Emails were sent to over 39,000 and a letter to ~100,000 MEC participants. The initial and a second invitation were sent to all living MEC participants, while a third invitation was sent to those who were 75 or younger. A paper survey was provided if requested. Participants registered online by providing their Email Address,

138 First name, Middle name, Last name, Sex, Birth year, and Zip Code. The entered data 139 linked each participant back to the MEC database. A Spanish registration page was 140 available for registration in Spanish. Each participant was sent a unique identifier and 141 login to answer the survey online. Participants who answered the baseline survey were 142 invited to fill out a weekly, then, monthly shorter follow-up online survey (Supplementary 143 Figure 1). Paper follow-up surveys were not available. The surveys started in May 2020 144 and ended in April 2021. The last baseline survey (the last opportunity to enter the 145 study) was collected on September 25, 2020.

146 Statistical Analysis

147 All baseline surveys with at least 50% completion were used for this analysis. 148 Descriptive statistics were utilized to summarize patient demographics, including means 149 ± standard deviations (SD) for continuous variables and frequencies and percentages 150 for categorical variables. A cross-sectional analysis was performed to investigate the 151 relationships between the outcomes of postponement of regular health care visits and 152 cancer screening tests/procedures/treatment with race and ethnicity, age, education, 153 and comorbidity. Chi-square tests and binary logistic regression models of the 154 outcomes of postponement and screening were used to calculate odds ratios (and 95%) 155 confidence intervals) and/or P-values (≤ 0.05 was taken as statistically significant) in 156 each sex to describe these relationships using the Statistical Analysis System (SAS), 157 version 9.4. Whites were taken as the reference group when comparing associations 158 across racial and ethnic groups. For comorbidities, the reference was reporting no 159 comorbidity.

RESULTS

161	Table 1 presents the number of COVID-19 survey participants by various
162	characteristics. A total of 6,974 MEC members answered the baseline survey, 6,068 via
163	the online survey, and 906 via the paper survey. Fewer men (43.5%) than women
164	(56.5%) responded. 76.6% of COVID survey participants were from Hawai'i and 23.6%
165	were from Los Angeles. The survey response rate was 7.2% for men and 6.3% for
166	women. The racial/ethnic group with the highest response rates was White (13.2% for
167	men; 12% for women, followed by Japanese American (8.9; 7.4), Native Hawaiian (7.3;
168	7.5), Other (2.7; 4.5), African American (2.7; 2.8), and Latino (2.2; 2.0). In
169	Supplementary Table 1, the distribution of the MEC cohort survivors in 2019 is
170	compared with the distribution of the COVID survey participants in 2021 by race and
171	education. For both males and females, the COVID survey respondents included a
172	larger representation of Whites and Japanese Americans and a smaller representation
173	of Latinos, African Americans, and Others compared to the entire 2019 surviving cohort.
174	The proportion of the sample that was Native Hawaiians was similar to the MEC
175	survivors. For education, a greater percentage of COVID-19 survey respondents had at
176	least some college education compared to the entire 2019 surviving cohort. This pattern
177	of higher attained education was observed for each racial/ethnic group.
178	Among participants in the baseline COVID-19 survey, the most common
179	race/ethnicity reported was White (45.2% of men; 42.7% of women), followed by
180	Japanese American (34.9%; 30.3%), Latino (7.9%; 7.4%), Native Hawaiian (6.4%;
181	8.1%), African American (3.5%; 6.5%), and Other (2.0%; 4.9%). The ethnicity category
182	of Other comprised a majority of Chinese Americans (38.1%) and Filipino (36.6%). The

183	mean age and education were similar in both sexes; however, men were more often
184	smokers and alcohol drinkers and had a higher BMI than women. Women had a greater
185	mean Healthy Eating Index-2010 score than men as reported in the MEC baseline
186	questionnaire (1993-1996).
187	Overall, 78.8% of men and 84.4% of women reported making changes to their
188	lifestyle or daily activities due to COVID-19 since March 2020. Examples of activities
189	were specifically about COVID-19 prevention measures such as covering a cough or
190	sneeze, more frequent hand washing, and social distancing. Among men, 4.2% and 6.3%
191	reported drinking more and drinking less during the COVID-19 pandemic, respectively.
192	The corresponding %'s for women were 4.3 and 5.2%. Only 3.7% of men and 2.6% of
193	women were current smokers.

194 Table 1. Demographics of Baseline COVID Survey Participants from Hawai'i and Los

195 Angeles (May-September 2020, N = 6,974)

196

		Male N (%) or Mean ± SD	Female N (%) or Mean ± SD		
		3,034 (43.5)	3,940 (56.5)		
Race/Ethnicity	White	1,371 (45.2)	1,683 (42.7)		
	Japanese American	1,059 (34.9)	1,195 (30.3)		
	Latino	241 (7.9)	291 (7.4)		
	Native Hawaiian	194 (6.4)	320 (8.1)		
	African American	107 (3.5)	257 (6.5)		
	Other ^a	62 (2.0)	194 (4.9)		
Age (years)	66 – 72.8	715 (23.57)	946 (24.01)		
	72.8 – 74.6	787 (25.94)	1008 (25.58)		
	74.6 – 77.9	796 (26.24)	979 (24.85)		
	77.9 – 102	736 (24.26)	1007 (25.56)		
Age (years)		76 ± 4.9	76 ± 5.3		
Years of Education ^b	, C	15.86 ± 2.1	15.48 ± 2.2		
Pack Years ^{b, c} (MEC	baseline 1993-1996)	8.57 ± 12.4	5.16 ± 9.9		
Alcohol Intake ^{b, c} (g/d	day) (MEC baseline 1993-1996)	12.65 ± 20.7	5.15 ± 11.8		
Number of Days an <i>i</i> the Past 2 Weeks ^{b, c}	Alcoholic Beverage was Consumed in	4.61 ± 5.6	2.83 ± 4.7		
Number of Days with Same Occasion in th	5 or More Drinks Consumed on the e Past 2 Weeks ^{b, c}	0.37 ± 1.8	0.07 ± 0.8		
	Ithy Eating Index-2010 score ^{b, c}	64.95 ± 10.8	68.66 ± 10.5		
Made Lifestyle and Healthcare Changes Due to COVID-19 Since March 2020 °		2,361 (78.8)	3,272 (84.4)		
Drinking Bahavier	Do Not Drink	1,185 (39.6)	2,051 (53.5)		
Drinking Behavior Change Due to	Drink More	125 (4.2)	163 (4.3)		
COVID-19 ^c	Drink Less	189 (6.3)	199 (5.2)		
00410-13	Same	1,492 (49.9)	1,421 (37.1)		
	BMI (kg/m²) ^{b, c}	26.8 ± 4.6	25.9 ± 5.8		
	Never	1,320 (44.0)	2,275 (58.7)		
Smoking Status ^c	Not currently, but in the past	1,568 (52.3)	1,505 (38.8)		
	Yes	110 (3.7)	99 (2.6)		
Have Healthcare	Yes	2,972 (99.2)	3,837 (99.2)		
Coverage ^c	l don't know / not sure	3 (0.1)	2 (0.1)		
•	No	21 (0.7)	28 (0.7)		
Has Primary Care Provider/Physician c2,908 (97.0)3,767 (97.4)					

Has Primary Care Provider/Physician c197a Comprised of a majority of Chinese Americans (38.1%) and Filipino (36.6%)

^bMean ± SD; other numbers are counts (and percentages)

¹⁹⁹ [°]For education attained, there are missing responses from 16 men and 27 women. For the other

200 questions asked in the MEC baseline and COVID survey, the missing responses range from 35-51 for

201 men and 57-106 for women.

Regarding the participant's health status, 3.5% and 19.7% of men had health

203	problems that require them to stay at home and limit their activities, respectively, at the
204	time of the COVID-19 baseline survey (Supplementary Table 2). The corresponding %'s
205	for women were 4.9 and 19.3%. In addition, the survey respondents had a wide range
206	of comorbidities in 2020, with hypertension (48% of men; 47.1% of women) being the
207	most prevalent, followed by diabetes (18.3%; 14.4%), and heart disease (20.8%;
208	10.6%). Lastly, the most frequently used medication was aspirin (37.9% of men; 28.1%
209	of women), followed by Blood Pressure Medication ending in –sartan (29.3%; 26.0%),
210	and Blood Pressure Medication ending in -pril (25.8%, 16.4%).

211 Overall, 54.2% of men and 61.2% of women participants reported that they had

to postpone their regular healthcare visits due to COVID-19. Primary care physician and

213 dentist visits were the most frequently postponed with 858 and 954 reports for men and

1,188 and 1,453 reports for women, respectively (Table 2).

Table 2. Distribution for Postponing Regular Health Care Visits Due to COVID-19 Pandemic by Sex (N = 6,974)

217

202

	Male N (%)	Female N (%)
Postponed regular health care visits	1,625 (54.2)	2,369 (61.3)
Missing	38	72
Primary care physician	858	1,188
Oncologist	54	105
Cardiologist	207	147
Endocrinologist	44	74
Dentist	954	1,453
Other	768	1416

218

Similarly, 5.7% of men and 11.0% of women reported having to postpone a

cancer screening or procedure due to COVID-19 (Table 3). The screening procedure

- the most frequently missed was mammography (n=264), followed by skin examination
 (n=207) and colorectal cancer screening (n=114). In the past five years, 917 survey
- participants had been diagnosed with cancer (Supplementary Table 2). Of note, 103
- 223 men (3.4%) and 135 women (3.4%) reported that they were currently receiving any of
- the following cancer treatments: chemotherapy (31 men; 30 women); immunotherapy:
- 225 (22 and 19) and radiation therapy (16 and 8). Among cancer patients still receiving
- treatment, 11.5% of men and 6.9% of women had to cancel at least one treatment
- session due to COVID-19 (Table 3).

228 Table 3. Distribution for Postponing Cancer Screening Test/Procedure/Treatment Due to

229 COVID-19 Pandemic by Demographics and Comorbidities (N = 6,974)

230

	Male N (%)	Female N (%)
Postponed any cancer screening test/procedure	169 (5.7)	422 (11.0)
Missing	48	87
Breast cancer screening (e.g., mammography, breast MRI)	-	264
Colorectal cancer screening (e.g., FOBT test, FIT test, colonoscopy, sigmoidoscopy)	42	72
Skin cancer screening (e.g., skin exam)	83	124
Prostate cancer screening (digital rectal examination, PSA)	25	-
Cervical cancer screening (e.g., PAP smear, pelvic exam)*	-	18
Imaging (e.g., CAT scan, DEXA, MRI)*	12	24
Other	24	29
Currently on chemotherapy,		
immunotherapy, or radiation therapy for cancer	103 (3.4)	135 (3.4)
Chemotherapy	31	30
Immunotherapy	22	19
Radiation Therapy	16	8
Postponed any cancer therapy session(s)	7 (11.5)	4 (6.9)
Missing	2973	3882

231

*Categories created by sorting text responses in the "Other Specify" answer choice.

232	Compared to White men, Native Hawaiian men were 41% (95% CI: 0.42, 0.84;
233	p=0.003) and Other men were 56% (95% CI: 0.25, 0.78, p=0.004) less likely, and
234	African American men were 154% (95% CI: 1.30, 4.99; p=0.007) more likely, to make
235	any changes to their lifestyle or daily activities, such as covering a cough or sneeze,
236	more frequent hand washing, and social distancing, since the COVID-19 pandemic
237	(Table 4). Compared to White women, Native Hawaiian women were 56% (95% CI:
238	0.33, 0.60; p<.0001) and Other women were 38% (95% CI: 0.41, 0.92; p=0.02) less
239	likely, to make any changes to their lifestyle or daily activities since the COVID-19
240	pandemic.
241	Each additional year of age was associated with less likelihood to make any

changes to their lifestyle or daily activities by 2% per year of age for men (OR=0.98, 95%

243 CI: 0.96, 1.00; p=0.02) and by 3% per year of age for women (OR=0.97, 95% CI: 0.96,

244 0.99; p=0.0005) (Table 4). Compared to men, women were 62% (95% CI: 1.42, 1.84;

p<.0001) more likely to make any changes to their lifestyle or daily activities. Each

additional year of education was associated with more likelihood to make changes to

their lifestyle or daily activities, by 12% per year of education in men (OR=1.12, 95% CI:

248 1.07, 1.17; p<.0001), and by 10% per year in women (OR=1.10, 95% CI: 1.06, 1.15;

249 p<.0001)

Compared to men with no comorbidity, men with heart disease were 41% (95% Cl: 1.11, 1.80; p=0.006), those with hypertension 34% (95% Cl: 1.11, 1.62; p=0.002), and those with lung disease, COPD, or asthma 41% (95% Cl: 1.01, 1.96; p=0.04), more likely to make changes to their lifestyle or daily activities (Table 4). Compared to women with no comorbidity, women with hypertension were 21% (95% Cl: 1.00, 1.47; p=0.05),

- and those with lung disease, COPD, or asthma 65% (95% CI: 0.70, 1.76; p=0.001),
- 256 more likely to make changes to their lifestyle or daily activities.

Table 4. Odds Ratio* for Change in Lifestyle or Daily Activities Since Onset of COVID-19 Pandemic by Demographics and Comorbidities

	Male (N = 3,000)			Female (N = 3,890)		
	Yes (n)	Odds Ratio (95% CI)	P-Value	Yes (n)	Odds Ratio (95% CI)	P-Value
Ethnicity						
White (N = 3,031)	1,083	1.00 (Ref)		1,448	1.00 (Ref)	
Japanese American (N = 2,228)	833	1.02 (0.83,1.26)	0.83	994	0.86 (0.69,1.07)	0.17
Latino (N = 520)	177	0.99 (0.70,1.40)	0.96	233	0.94 (0.65,1.35)	0.73
Native Hawaiian (N = 509)	135	0.59 (0.42,0.84)	0.003	235	0.44 (0.33,0.60)	<.0001
African American (N = 354)	96	2.54 (1.30,4.99)	0.01	211	0.96 (0.64,1.43)	0.82
Other (N = 248)	37	0.44 (0.25,0.78)	0.01	151	0.62 (0.41,0.92)	0.02
Age (Years) (N = 6,890)	2,361	0.98 (0.96,1.00)	0.02	3,272	0.97 (0.96,0.99)	0.001
Maximum Education Obtained (Years) (N = 6,847)	2,347	1.12 (1.07,1.17)	<.0001	3,248	1.10 (1.06,1.15)	<.0001
Comorbidities						
None (N=2,307)**	694	1.00 (Ref)		1,140	1.00 (Ref)	
Heart Disease (N = 1,035)	51	1.41 (1.11,1.80)	0.01	356	1.19 (0.86,1.63)	0.29
Hypertension ($N = 3,271$)	1,169	1.34 (1.11,1.62)	0.002	1,545	1.21 (1.00,1.47)	0.05
Diabetes (N = $1,106$)	424	0.87 (0.68,1.10)	0.25	462	0.90 (0.69,1.16)	0.40
Lung Disease, COPD, or Asthma (N = 819)	249	1.41 (1.01,1.96)	0.04	466	1.65 (1.22,2.23)	0.001
Kidney Disease (N = 340)	138	1.37 (0.87,2.13)	0.17	150	1.11 (0.70,1.76)	0.65
Diagnosed w/ Cancer in past 5 yrs. (N = 921)	383	1.09 (0.84,1.40)	0.51	383	1.21 (0.89,1.64)	0.22

*Adjusted for the other variables in the table.

261

*Male (Reference) vs. Female: OR = 1.62 (95% CI: 1.42,1.84; p<.0001) **Number of respondents who did not answer affirmatively for any listed co-morbidities.

264	Similarly, compared to White men, Latino men were 26% (95% CI: 0.55, 0.99;
265	p=0.04) and Native Hawaiian men 36% (95% CI: 0.47, 0.88; p=0.005) less likely to
266	postpone regular health care visits due to the COVID-19 pandemic (Table 5). Compared
267	to White women, Native Hawaiian women were 40% (95% CI: 0.47, 0.78; p=0.0001)
268	less likely to postpone regular healthcare visits due to the COVID-19 pandemic.
269	Each additional year of age in women was associated with a lower likelihood to
270	postpone regular healthcare visits by 2% per year (OR=0.98, 95% CI: 0.97, 0.99;
271	p=0.0006) (Table 5). Each additional year of education in men was associated with a
272	higher likelihood to postpone regular health care visits, by 45% per year (OR=1.04, 95%
273	CI: 1.00, 1.08; p=0.04). Compared to men, women were 43% (95% CI: 1.29, 1.58;
274	p<.0001) more likely to postpone regular health care visits.
275	Compared to men with no comorbidity, men with heart disease were 37% (95%
276	CI: 1.13, 1.65; p=0.0011) more likely to postpone regular health care visits (Table 5).
277	Compared to women with no comorbidity, women with hypertension were 16% (95% CI:
278	1.00, 1.33; p=0.04), those with kidney disease 49% (95% CI: 1.05, 2.11; p=0.03), and
279	those diagnosed with cancer in the past 5 years 51% (95% CI: 1.21, 1.88; p=0.0003),
280	more likely to postpone regular health care visits.

281 Table 5. Odds Ratio* for Postponing Regular Health Care Visits Due to COVID-19 Pandemic by Demographics and

282 Comorbidities

2	o	2
2	ð	3

		Male (N = 2,998)		Female (N = 3,881)			
	Yes (n)	Odds Ratio (95% CI)	P-Value	Yes (n)	Odds Ratio (95% CI)	P-Value	
Ethnicity							
White (N = 3,026)	770	1.00 (Ref)		1,042	1.00 (Ref)		
Japanese American (N = 2,224)	560	0.88 (0.74,1.04)	0.13	715	0.93 (0.80,1.09)	0.38	
Latino (N = 519)	114	0.74 (0.55,0.99)	0.04	187	1.32 (0.99,1.76)	0.06	
Native Hawaiian (N = 508)	88	0.64 (0.47,0.88)	0.005	163	0.60 (0.47,0.78)	0.0001	
African American (N = 354)	61	1.01 (0.67,1.52)	0.98	155	1.01 (0.75,1.34)	0.97	
Other (N = 248)	32	0.87 (0.51,1.49)	0.62	107	0.77 (0.56,1.05)	0.10	
Age (Years) (N = 6,879)	1,625	1.00 (0.99,1.02)	0.85	2,369	0.98 (0.97,0.99)	0.001	
Maximum Education Obtained (Years) (N = 6,836)	1,617	1.04 (1.00,1.08)	0.04	2,354	1.03 (1.00,1.06)	0.10	
Comorbidities							
None (N=2,301)**	445	1.00 (Ref)		800	1.00 (Ref)		
Heart Disease (N =1,032)	382	1.37 (1.13,1.65)	0.001	266	1.18 (0.94,1.49)	0.16	
Hypertension ($N = 3,266$)	819	1.16 (1.00,1.35)	0.06	1,141	1.16 (1.00,1.33)	0.04	
Diabetes (N = $1,106$)	314	1.15 (0.94,1.40)	0.18	346	1.00 (0.82,1.22)	1.00	
Lung Disease, COPD, or Asthma (N = 821)	179	1.25 (0.98,1.61)	0.08	335	1.12 (0.92,1.36)	0.26	
, Kidney Disease (N = 339)	100	1.16 (0.83,1.62)	0.40	123	1.49 (1.05,2.11)	0.03	
Diagnosed w/ Cancer in past 5 yrs. (N = 920)	268	1.04 (0.85,1.27)	0.73	305	1.51 (1.21,1.88)	0.0003	

*Adjusted for the other variables in the table.

284 285

*Male (Reference) vs. Female: OR = 1.43 (95% CI: 1.29,1.58; p<.0001) **Number of respondents who did not answer affirmatively for any listed co-morbidities. 286

287	Compared to White men, Japanese American men were 72% (95% CI: 0.18,
288	0.45; p<.0001) less likely to postpone any cancer screening test/procedure due to the
289	COVID-19 pandemic (Table 6). Compared to White women, Japanese American
290	women were 40% (95% CI: 0.46, 0.78; p=0.0002) less likely to postpone any cancer
291	screening test/procedure due to the COVID-19 pandemic.
292	Women were 4% less likely for each additional year of age (95% CI: 0.94, 0.98;
293	p=0.001) to postpone any cancer screening test/procedure (Table 6). Women were 10%
294	more likely for each additional year of education (95% CI: 1.05, 1.16; p=0.0004) to
295	postpone any cancer screening test/procedure. Compared to men, women were 137%
296	(95% CI: 1.95, 2.88; p<.0001) more likely to postpone any cancer screening
297	test/procedure.
298	Compared to men with no comorbidity, men diagnosed with cancer in the past 5
299	years were 254% (95% CI: 2.52, 4.95; p<.0001) more likely to postpone any cancer
300	screening test/procedure (Table 6). Compared to women with no comorbidity, women
301	with lung disease, COPD, or asthma were 50% (95% CI: 1.14, 1.98; p=0.004) and those
302	diagnosed with cancer in the past 5 years were 222% (95% CI: 2.50, 4.14; p<.0001)
303	more likely to postpone any cancer screening test/procedure.

304 Table 6. Odds Ratio* for Postponing Cancer Screening Test/Procedure Due to COVID-19 Pandemic by Demographics and Comorbidities 305

306

	Male (N = 2,988))	
	Yes (n)	Odds Ratio (95% CI)	P-Value	Yes (n)	Odds Ratio (95% Cl)	P-Value
Ethnicity						
White (N = 3,018)	123	1.00 (Ref)		227	1.00 (Ref)	
Japanese American (N = 2,220)	23	0.28 (0.18,0.45)	<.0001	90	0.60 (0.46,0.78)	0.0002
Native Hawaiian (N = 508)	7	0.48 (0.21,1.05)	0.07	32	0.73 (0.48,1.11)	0.14
African American (N = 353)	7	0.90 (0.40,2.03)	0.81	27	1.01 (0.65,1.57)	0.96
Latino (N = 509)	8	0.48 (0.23,1.03)	0.06	25	0.90 (0.57,1.44)	0.66
Other	1	0.24 (0.03,1.80)	0.17	21	0.86 (0.53,1.41)	0.55
Age (Years) (N = 6,854)	169	0.96 (0.93,1.00)	0.06	422	0.96 (0.94,0.98)	0.001
Maximum Education Obtained (Years) (N = 6,811)	166	1.03 (0.95,1.12)	0.50	421	1.10 (1.05,1.16)	0.0004
Comorbidities						
None (N=2,295)**	47	1.00 (Ref)		121	1.00 (Ref)	
Heart Disease (N = 1,028)	29	0.82 (0.53,1.27)	0.37	52	1.21 (0.87,1.69)	0.27
Hypertension ($N = 3,255$)	75	1.07 (0.76,1.50)	0.70	195	1.07 (0.86,1.34)	0.56
Diabetes (N = $1,099$)	22	0.88 (0.54,1.44)	0.61	53	0.83 (0.59,1.16)	0.27
Lung Disease, COPD, or Asthma (N = 815)	17	0.84 (0.48,1.47)	0.54	79	1.50 (1.14,1.98)	0.004
Kidney Disease (N = 337)	7	0.89 (0.40,2.00)	0.78	18	0.94 (0.55,1.58)	0.80
Diagnosed w/ Cancer in past 5 yrs. (N = 918)	71	3.54 (2.52,4.95)	<.0001	112	3.22 (2.50,4.14)	<.0001

307 *Adjusted for the other variables in the table.

*Male (Reference) vs. Female: OR = 2.37 (95% CI: 1.95,2.88; p<.0001)

308 309 **Number of respondents who did not answer affirmatively for any listed co-morbidities.

DISCUSSION
The results of this study suggest unique relationships between participant
characteristics, such as sex, age, years of education, race/ethnicity, and comorbidities
with the likelihood of making changes to lifestyle or daily activities and of postponing
regular health care visits and cancer screenings/treatments during the COVID-19
pandemic. Responses were compared between males and females and by
race/ethnicity to describe the differences between these groups.
African American men (compared to White men), women (compared to men),
men and women with more education, men and women with heart disease,
hypertension, or lung disease, COPD, or asthma (compared to men or women with no
comorbidity) were more likely to make changes to their lifestyle or daily activities during
the COVID-19 pandemic. As expected, participants with one or more risk factors, such
as cancer or lung disease, were more likely to make changes to their lifestyle during the
pandemic as they were reported to be at increased risk of severe illness from COVID-19.
Men with more education, women (compared to men), men with heart disease,
and women with hypertension, kidney disease, and diagnosed with cancer in the past 5
years were more likely to postpone regular health care visits. As expected, participants
with comorbidity were more likely to postpone healthcare visits, as they were
recommended to avoid public places to protect themselves from the virus.
Lastly, women with more education, women (compared to men), women and
men diagnosed with cancer in the past 5 years, and women with lung disease, COPD,
or asthma were more likely to postpone any cancer screening test/procedure.

Native Hawaiian men and women and those of Other race/ethnicity (compared to White men or women), and older men and women were less likely to make changes to their lifestyle or daily activities during the COVID-19 pandemic. Latino and Native Hawaiian men, Native Hawaiian women, and older women were less likely to postpone regular healthcare visits during the COVID-19 pandemic. Lastly, Japanese American men and women and older women were less likely to postpone any cancer screening test/procedure during the COVID-19 pandemic.

339 Effect on Healthcare Visits

340 From May 2020 to September 2020, 54.2% of male and 61.3% of female MEC 341 survey respondents reported postponing regular health care visits. These numbers are consistent with a report published by The Commonwealth Fund in May 2020.¹³ In the 342 343 U.S., early in the pandemic from February 2020, the number of visits to ambulatory care practice declined by nearly 60%.¹³ Declines in visits varied by geographic area and 344 345 clinical specialty. By April 2020, a rebound of in-person visits had occurred and appears 346 largest in the South Central (East and West) census division (Texas, Oklahoma, 347 Arkansas, Louisiana, Mississippi, Alabama, Tennessee, and Kentucky) but the number 348 of visits was still roughly one-third lower than before the pandemic. As in-person visits 349 declined, telehealth visits increased rapidly before plateauing. By mid-May 2020, a 350 rebound in visits had occurred across all specialties. But the relative decline in visits 351 remained largest among surgical and procedural specialties and pediatrics. The greater 352 effect on surgical and procedural specialties was observed in the MEC survey 353 responses, as visits with eye specialists, dermatologists, cardiologists, and dentists, 354 were more often reported to be postponed. In the Commonwealth Fund study, the

355 relative decline was smaller in other specialties, such as adult primary care. The MEC 356 study findings differ as visits for this specialty were the most frequently postponed in our 357 data. In addition, researchers from Harvard Medical School examined the trends in 358 outpatient care delivery and telemedicine in a cohort of 16,740,365 enrollees captured 359 from the OptumLabs Data Warehouse. The weekly rate of telemedicine visits increased 360 during the pandemic period starting from January 1, 2020, and peaking in the week of 361 April 15, 2020, before declining by the week of June 10, 2020. By the last 4 weeks of 362 the study period, May 20 through June 16, Hawai'i had a -73.2% change and California 363 had a -31.0% change from baseline in weekly total visits per 1000 members. For visits 364 delivered via telemedicine, Hawai'i had a 24.5% increase from baseline and California had a 29.5% increase.¹⁴ Although the COVID-19 pandemic led to widespread 365 366 disruptions in medical care, it is possible that patients who avoided hospital visits had a 367 positive outcome of lower risk of catching COVID-19. There may have been some 368 benefit to the strategy of keeping patients out of the hospitals and physician offices. In 369 the baseline MEC COVID Survey, only 49 men and 68 women, overall, reported an 370 episode of COVID-19.

The likelihood of postponing healthcare visits being related to the presence of comorbidities was also investigated. In the MEC Survey, men with heart disease (by 373) 37%), women with hypertension (by 16%), kidney disease (by 49%), and those diagnosed with cancer in the past 5 years (by 51%) were more likely to postpone regular health care visits due to the COVID-19 pandemic. These findings were consistent with a study that examined factors associated with postponed health checkups during the COVID-19 pandemic in Germany.¹⁵ Researchers found the

probability of postponed health checkups was positively associated with the presence of
chronic disease (OR: 1.68, 95% CI: 1.15, 2.47), higher concern for a COVID-19
infection (OR: 1.44, 95% CI: 1.16, 1.78), and higher presumed severity of COVID-19
(OR: 1.17, 95% CI: 1.01, 1.35).

382 Effect on Cancer Screening

383 Not many MEC survey respondents reported postponing a cancer screening test 384 or procedure due to COVID-19. Only 5.7% of men and 11.0% of women did so. These 385 numbers were lower than expected but could be explained by the older age of our 386 sample. The recommended cut-off age for breast and colorectal cancer screening is 75 387 years old. Half of the respondents were aged 75 and older. However, when focusing on 388 participants 75 years and younger, the numbers were similar to the overall sample size: 389 6.1% vs. 5.7% of men overall and 12.3% vs. 11.0% of women overall. The screening 390 procedure the most frequently missed was mammography, followed by skin 391 examination and colorectal cancer screening. Postponement of these cancer screening 392 procedures is consistent with data from a published study looking at a sample of health 393 claims clearinghouse records from 18 states containing 184 million claims from 30 394 million patients in 2019 and 94 million claims from 20 million patients for the first 6 months in 2020.¹⁶ Mammograms and Pap smears were down nearly 80 percent in April 395 396 2020 compared to 2019. However, numbers for both services recovered throughout the 397 summer and fall, with Pap smears and mammograms rebounding above 2019 levels in 398 August 2020 and November 2020, respectively. Colonoscopies were down almost 90% 399 in mid-April 2020, compared to 2019, and in December 2020 were still down about 15% 400 compared to the previous year, representing a substantial but incomplete rebound in

401 care delivered. The overall number of colonoscopies performed in 2020 declined by402 almost 25% from 2019.

403 The likelihood of postponing cancer screenings was also analyzed in relation to 404 age. In the MEC study, women with each additional year of age were less likely by 4% 405 per year of age (OR=0.96, 95% CI: 1.00, 1.08; p=0.04) to postpone any cancer 406 screening test/procedure. This finding is consistent with a study examining determinants of postponed cancer screening during the COVID-19 pandemic in Germany.¹⁷ Multiple 407 408 logistic regressions were conducted with postponed cancer screenings since March 409 2020 due to the COVID-19 pandemic as the outcome measure (0= no, attended as 410 planned, 1 = postponed). Regressions revealed that the likelihood of postponing cancer 411 screening was positively associated or more likely with higher concern for a COVID-19 412 infection (OR: 1.65, 95% CI: 1.16, 2.35), whereas it was negatively associated or less 413 likely with older age (e.g., 65 years and over, OR: 0.38, 95% CI: 0.16, 0.89, compared 414 to individuals 30 to 49 years).

415 The backlog of postponed or delayed cancer screenings will have a long-term 416 clinical impact and potentially increase the cancer burden. A study from Canada 417 examined the impact of episodic screening interruptions for breast and colorectal 418 cancer.¹⁸ Using a simulation model, researchers projected a surge of cancer cases 419 when screening resumes. For breast cancer screening, the simulation model suggests 420 that a three-month interruption of breast cancer screening due to COVID-19 would 421 result in 644,000 fewer screens being performed in Canada in 2020. A three-month 422 interruption starting in 2020 could increase cases diagnosed at advanced stages (310 423 more) and breast cancer deaths (110 more) in Canada from 2020 to 2029. A six-month

424 interruption starting in 2020 could lead to 670 extra advanced breast cancers and 250 425 additional breast cancer deaths in Canada from 2020 to 2029. For colorectal cancers, 426 without service interruption, the simulation model estimated that 68,000 colonoscopies 427 would have been performed in the six months since March 2020 in Canada. A six-428 month suspension of primary screening could increase cancer incidence by 2,200 cases 429 with 960 more cancer deaths over the lifetime. Longer interruptions, and reduced 430 volumes of patients when screening resumes, would further increase excess cancer 431 deaths. Since cancer diagnoses and deaths in the MEC are identified through linkages 432 to cancer registries in HI and California, we will be able to examine whether a greater 433 proportion of cancers were diagnosed at a late stage in the aftermath of the pandemic 434 and investigate any differences among ethnic/racial groups. Similarly, through the 435 linkage of the cohort to Medicare, we will be able to identify MEC members who 436 developed COVID-19 and investigate long-term complications and survival across age 437 and race.

438 Limitations

439 There are several limitations to our study. Although our study population is 440 diverse, some subgroups of race/ethnicity (African Americans and Latinos) were under-441 represented compared to other subgroups. Additionally, the study sample is not fully 442 representative of the entire MEC cohort, as the participants were more educated with 443 higher percentages with at least some college education across all races/ethnicities. 444 The survey respondents included a larger representation of Whites and Japanese 445 Americans and a smaller representation of Latinos and African Americans compared to 446 the MEC survivors in 2019. The effect of COVID-19 on cervical cancer screening was

not investigated due to the older age of our participants. The data was self-reported so
there is a chance of misclassification due to recall error. Lastly, the response rates were
low across all races/ethnicities, and only 0.9% of male and 1.7% of female survey
participants are living in a retirement or care home so these populations were most
certainly underrepresented.

452 <u>CONCLUSION</u>


453 The MEC COVID-19 survey demonstrated the possibility of using a mature 454 cohort study of well-characterized individuals to characterize the effect of a public health 455 emergency. The study revealed associations of factors like sex, race/ethnicity, age, 456 education level, and comorbidities with cancer-related screening and healthcare among 457 MEC participants during the COVID-19 pandemic in Hawai'i and Los Angeles. The MEC 458 COVID-19 survey results were consistent with other studies regarding the 459 postponement of healthcare visits, surgical procedures, and cancer screenings during 460 the pandemic. In the wake of the pandemic, increased monitoring of patients in high-risk 461 groups for cancer and other diseases is of the utmost importance as the chance of 462 undiagnosed cases and poor prognosis due to delayed screening and/or treatment 463 increases.

464

<u>APPENDIX</u>

466 Supplementary Tables and Figure

467 Supplementary Figure 1. Timeline of the MEC COVID-19 Study



468

465

06/16/20

Supplementary Table 1. Comparison of Ethnicity and Educational Level between 2019 MEC Cohort Survivors and 2021 COVID Survey Participants

Ethnicity	(%	Educational Level (%)								
	2019 MEC Cohort (N = 111,433)	COVID Survey Cohort (N = 6,974)	≤8 years		9–12 years Voca		Vocat	tional	At least some college 	
Male and Female			MEC	COVID	MEC	COVID	MEC	COVID	MEC	COVID
White	23.1	43.8	1.7	0	18.8	6.8	4.3	2.4	75.2	90.8
Japanese American	28.2	32.3	1.3	0.1	27.4	7.0	13.8	9.0	57.5	83.9
Latino	23.6	7.6	35.3	8.1	30.9	20.4	6.8	5.9	27.0	65.6
Native Hawaiian	6.7	7.4	1.3	0.2	42.3	21.1	9.4	8.2	47.0	70.5
African- American	11.7	5.2	3.5	0	28.0	10.0	6.1	3.3	62.4	86.7
Other	6.7	3.7	10.0	0.4	22.3	10.6	6.9	4.7	60.8	84.3

Supplementary Table 2. Distribution of Baseline COVID Survey Participants by

Health Status, Comorbidities, and Medication Use, Hawai'i and Los Angeles (N =

6,974)

	Male N (%)	Female N (%)
Health Status:		
Has Health Problems that Require Them to Stay at Home	104 (3.5)	189 (4.9)
Missing	35	64
Needs Assistance with Daily Living Activities on a Regular Basis	96 (3.2)	156 (4.0)
Missing	35	61
Cane, Walker, or Wheelchair/Scooter Usage to Get About	193 (6.4)	363 (9.4)
Missing	36	57
History of Health Problems that Limit Activities	591 (19.7)	747 (19.3)
Missing	36	62
Comorbidities		
History of Heart Disease Missing	622 (20.8) 38	412 (10.6) 69
History of Hypertension Missing	1,441 (48.0) 37	1,824 (47.1) 63
History of Diabetes Missing	548 (18.3) 35	559 (14.4) 63
History of Lung Disease, COPD, or Asthma	297 (9.9)	523 (13.5)
Missing	37	67
History of Kidney Disease Missing	164 (5.5) 36	175 (4.5) 65
Diagnosed with Cancer in the Past 5 Years	478 (15.9)	439 (11.3)
Missing	35	62

478 Supplementary Table 2. (Continued)

479
4/7

Iedication Use Taking immunosuppressant		
medications (including steroids,	110 (3.7)	182 (4.7)
methotrexate, biologic agents)		
Missing	44	78
Taking heartburn medication	307 (10.3)	383 (9.9)
Pepcid (famotidine)	. ,	
Missing	39	64
Taking Aspirin (baby aspirin or std dose)	1,135 (37.9)	1,091 (28.1)
Missing	36	59
Wissing	00	
Taking NSAIDs like ibuprofen,	267 (8.9)	418 (10.8)
nurofen, diclofenac, naproxen Missing	35	65
Taking Blood Thinning Medication (such as Coumadin/Warfarin, Eliquis/apixaban) Missing	480 (16.0) 42	293 (7.6) 75
Taking Blood Pressure		
Medication ending in -pril (such as enalapril, lisinopril, captopril,	771 (25.8)	632 (16.4)
ramipril)	40	0.4
Missing	46	84
Taking Blood Pressure		
Medication ending in	874 (29.3)	1,004 (26.0)
–sartan (such as losartan valsartan, irbesartan)	· · /	, , , , , , , , , , , , , , , , , , , ,
Missing	46	83

Supplementary Table 3. Distribution for Postponing Regular Health Care Visits 484

Due to COVID-19 Pandemic by Sex (N = 6,974) 485

486

	Male N (%)	Female N (%)
Other*:	768	1416
Dermatology	156	218
Eye	248	411
ENT	44	67
OB-GYN	0	105
Orthopedist	36	62
Podiatrist	31	39
Urologist	70	27
Neurologist	27	28
Rheumatologist	15	50
Pulmonologist	19	35
Audiologist	24	50
Allergist	2	15
Gastroenterologist	5	10
Laboratory Testing/Imaging	21	140
Physical/Massage/Chiropractic Therapy	34	89
Other specialists	15	23
Other healthcare providers	21	47

487 *All other categories were sorted from the text responses for specifying the "Other specialist or health care provider."

489 490		REFERENCES
490 491 492	1.	Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. <i>Lancet Infect Dis.</i> 2020;20(5):533-534. doi:10.1016/S1473-3099(20)30120-1
493 494 495	2.	Coronavirus disease (COVID-19): Risks and safety for older people. World Health Organization. Accessed November 11, 2020. https://www.who.int/news-room/questions-and- answers/item/coronavirus-disease-covid-19-risks-and-safety-for-older-people
496 497 498	3.	Schmidt AL, Bakouny Z, Bhalla S, Steinharter JA, Tremblay DA, Awad MM, Kessler AJ, Haddad RI, et al. Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. <i>Cancer Cell</i> . 2020;38(6):769-770. doi:10.1016/j.ccell.2020.10.023
499 500	4.	Newman LA, Winn RA, Carethers JM. Similarities in Risk for COVID-19 and Cancer Disparities. <i>Clin Cancer Res.</i> 2021;27(1):24-27. doi:10.1158/1078-0432.CCR-20-3421
501 502 503 504	5.	Corley DA, Sedki M, Ritzwoller DP, Greenlee RT, Neslund-Dudas C, Rendle KA, Honda SA, Schottinger JE, et al. Cancer Screening During the Coronavirus Disease-2019 Pandemic: A Perspective From the National Cancer Institute's PROSPR Consortium. <i>Gastroenterology</i> . 2021;160(4):999-1002. doi:10.1053/j.gastro.2020.10.030
505 506 507 508	6.	Nodora JN, Gupta S, Howard N, Motadel K, Propst T, Rodriguez J, Schultz J, Velasquez S, et al. The COVID-19 Pandemic: Identifying Adaptive Solutions for Colorectal Cancer Screening in Underserved Communities. <i>JNCI J Natl Cancer Inst.</i> 2021;113(8):962-968. doi:10.1093/jnci/djaa117
509 510 511	7.	London JW, Fazio-Eynullayeva E, Palchuk MB, Sankey P, McNair C. Effects of the COVID-19 Pandemic on Cancer-Related Patient Encounters. <i>JCO Clin Cancer Inform</i> . 2020;(4):657-665. doi:10.1200/CCI.20.00068
512 513 514 515 516	8.	Pike MC, Kolonel LN, Henderson BE, Wilkens LR, Hankin JH, Feigelson HS, Wan PC, Stram DO, Nomura AMY. Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. <i>Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev</i> <i>Oncol.</i> 2002;11(9):795-800.
517 518	9.	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. <i>CA Cancer J Clin</i> . 2020;70(1):7-30. doi:10.3322/caac.21590
519 520 521 522	10.	Damiani G, Basso D, Acampora A, Bianchi CBNA, Silvestrini G, Frisicale EM, Sassi F, Ricciardi W. The impact of level of education on adherence to breast and cervical cancer screening: Evidence from a systematic review and meta-analysis. <i>Prev Med.</i> 2015;81:281-289. doi:10.1016/j.ypmed.2015.09.011
523 524 525	11.	Rodriguez N, Smith J. The Association Between Education and Colorectal Cancer Screening among United States Veterans Aged 50-75 Years Old: 286. <i>Off J Am Coll Gastroenterol ACG</i> . 2016;111:S134.

- 526 12. Kolonel LN, Henderson BE, Hankin JH, Nomura AMY, Wilkens LR, Pike MC, Stram DO,
 527 Monroe KR, et al. A Multiethnic Cohort in Hawaii and Los Angeles: Baseline
 528 Characteristics. *Am J Epidemiol.* 2000;151(4):346-357.
- 529 doi:10.1093/oxfordjournals.aje.a010213
- Mehrotra A, Chernew M, Linetsky D, Hatch H, Cutler D. The impact of the COVID-19
 pandemic on outpatient visits: a rebound emerges. *Commonwealth Fund*. Published online
 2020. doi:10.26099/DS9E-JM36
- 14. Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I, Barnett ML. Trends in
 Outpatient Care Delivery and Telemedicine During the COVID-19 Pandemic in the US. *JAMA Intern Med.* 2021;181(3):388-391. doi:10.1001/jamainternmed.2020.5928
- 536 15. Hajek A, De Bock F, Kretzler B, König HH. Factors associated with postponed health
 537 checkups during the COVID-19 pandemic in Germany. *Public Health*. 2021;194:36-41.
 538 doi:10.1016/j.puhe.2021.02.023
- 16. Martin K, Kurowski D, Given P, Kennedy K, Clayton E. The Impact of COVID-19 on the
 Use of Preventive Health Care. HCCI. Accessed March 15, 2022.
 https://healthcostinstitute.org/hcci-research/the-impact-of-covid-19-on-the-use-ofpreventive-health-care
- 543 17. Hajek A, De Bock F, Huebl L, Kretzler B, König HH. Determinants of Postponed Cancer
 544 Screening During the COVID-19 Pandemic: Evidence from the Nationally Representative
 545 COVID-19 Snapshot Monitoring in Germany (COSMO). *Risk Manag Healthc Policy*.
 546 2021;Volume 14:3003-3011. doi:10.2147/RMHP.S297326
- 547 18. Yong JH, Mainprize JG, Yaffe MJ, Ruan Y, Poirier AE, Coldman A, Nadeau C, Iragorri N,
 548 et al. The impact of episodic screening interruption: COVID-19 and population-based cancer
 549 screening in Canada. *J Med Screen*. 2021;28(2):100-107. doi:10.1177/0969141320974711
- 550

COVID-19 SYMPTOM TRACKER APP

ONLINE BASELINE QX

ONLINE FOLLOW-UP QX

Email Blast (1 st) 39,232 04/06/20 – 04/09/20	Letter Mailing (1 st) 108,426 04/09/20 – 04/14/20	Email Blast (2 nd) 39,101 05/07/20 – 05/09/20 05/22/20	(Reminder) Email Blast (3 rd) 12,876 06/15/20 06/17/20	Letter Mailing (2 nd) 103,723 05/08/20 – 05/13/20 05/22/20	(Reminder) Letter Mailing (3 rd) 23,877 06/15/20 ≤ 75 years old	Email Blast (3 rd) 05/15/20 – 04/27/21
English (HI + LA) 38,405 04/06/20 – 04/09/20	HI 53,800 04/09/20 – 04/10/20	English (HI + LA) 38,264 05/07/20 – 05/09/20	12,658	A) HI 51,726 05/08/20	HI 15,335 06/15/20	
LA Spanish 827 04/08/20	LA English 42,748 04/14/20	LA Spanish 837 05/22/20	LA Spanish 218 06/17/20	LA English 40,715 05/13/20	LA English 6,899 06/19/20	
	LA Spanish 11,878 04/14/20			LA Spanish 11,282 05/22/20	LA Spanish 1,643 06/19/20	